HC Wainwright Has Negative Opinion of TNGX FY2026 Earnings

Tango Therapeutics, Inc. (NASDAQ:TNGX) – HC Wainwright reduced their FY2026 earnings per share (EPS) estimates for Tango Therapeutics in a note issued to investors on Tuesday, November 10th. HC Wainwright analyst R. Burns now forecasts that the company will post earnings per share of ($1.50) for the year, down from their prior forecast of ($1.34). HC Wainwright has a “Buy” rating and a $67.00 price objective on the stock. The consensus estimate for Tango Therapeutics’ current full-year earnings is ($1.44) per share. HC Wainwright also issued estimates for Tango Therapeutics’ Q4 2026 earnings at ($0.41) EPS, Q1 2027 earnings at ($0.42) EPS, Q2 2027 earnings at ($0.43) EPS, Q3 2027 earnings at ($0.44) EPS, Q4 2027 earnings at ($0.46) EPS and FY2027 earnings at ($1.75) EPS.

A number of other research firms also recently weighed in on TNGX. JPMorgan Chase & Co. boosted their target price on shares of Tango Therapeutics from $46.00 to $47.00 and gave the stock an “overweight” rating in a report on Tuesday. Stifel Nicolaus set a $55.00 price target on shares of Tango Therapeutics in a report on Friday, October 23rd. William Blair started coverage on Tango Therapeutics in a research report on Friday, October 16th. They issued an “outperform” rating for the company. Guggenheim boosted their price objective on Tango Therapeutics from $32.00 to $35.00 and gave the stock a “buy” rating in a research note on Wednesday, August 12th. Finally, Jefferies Financial Group restated a “buy” rating and set a $65.00 price objective on shares of Tango Therapeutics in a research report on Tuesday. Thirteen analysts have rated the stock with a Buy rating, two have issued a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, Tango Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $45.54.

Tango Therapeutics Trading Up 5.9%

Shares of Tango Therapeutics stock opened at $25.73 on Thursday. The firm has a market cap of $4.36 billion, a PE ratio of -18.78 and a beta of 1.26. The stock has a 50 day moving average of $23.42 and a 200 day moving average of $22.66. Tango Therapeutics has a 12 month low of $7.49 and a 12 month high of $34.39.

Tango Therapeutics (NASDAQ:TNGX) last released its quarterly earnings data on Monday, November 9th. The company reported ($0.39) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.04).

Institutional Trading of Tango Therapeutics

A number of large investors have recently modified their holdings of TNGX. BlackRock Inc. purchased a new position in Tango Therapeutics during the 2nd quarter worth $388,826,000. TRV GP IV LLC purchased a new stake in shares of Tango Therapeutics in the 2nd quarter worth $120,181,383,000. Jupiter Topco LLC purchased a new stake in shares of Tango Therapeutics in the 2nd quarter worth $157,989,000. Seven Fleet Capital Management LP grew its position in shares of Tango Therapeutics by 302.2% during the 2nd quarter. Seven Fleet Capital Management LP now owns 3,228,144 shares of the company’s stock worth $95,661,000 after buying an additional 2,425,484 shares in the last quarter. Finally, Jefferies Financial Group Inc. bought a new position in shares of Tango Therapeutics during the 2nd quarter worth $62,849,000. Hedge funds and other institutional investors own 78.99% of the company’s stock.

Insider Transactions at Tango Therapeutics

In other news, insider Adam Crystal sold 5,000 shares of the firm’s stock in a transaction that occurred on Monday, November 2nd. The shares were sold at an average price of $22.42, for a total transaction of $112,100.00. Following the transaction, the insider directly owned 115,743 shares of the company’s stock, valued at approximately $2,594,958.06. This trade represents a 4.14% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Jessica Newcomb sold 7,031 shares of Tango Therapeutics stock in a transaction that occurred on Monday, November 2nd. The shares were sold at an average price of $22.42, for a total transaction of $157,635.02. Following the sale, the insider directly owned 52,090 shares of the company’s stock, valued at $1,167,857.80. This represents a 11.89% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 47,231 shares of company stock valued at $1,129,029 in the last quarter. 6.50% of the stock is currently owned by company insiders.

Key Tango Therapeutics News

Here’s some of the latest news about TNGX:

• Positive Sentiment: JPMorgan raised its price target to $47 from $46 and reiterated an “overweight” rating, signaling continued confidence in the stock. JPMorgan analyst update
• Positive Sentiment: TNGX was reported to have moved above its 50-day moving average despite a recent quarterly earnings miss, a potentially supportive technical signal. Stock moves above 50-day average
• Negative Sentiment: HC Wainwright cut its EPS estimates across 2026 and 2027, including its FY2027 loss estimate to $1.75 per share from $1.54. It also trimmed its price target to $67 from $68, although it kept a “buy” rating. The revisions suggest expectations for larger losses and may weigh on sentiment. HC Wainwright lowers expectations

Tango Therapeutics Company Profile

Tango Therapeutics is a biotechnology company focused on discovering and developing precision medicines for cancer. Based in Cambridge, Massachusetts, the company aims to develop treatments that exploit genetic differences between cancer cells and healthy cells. Its research centers on synthetic lethality, an approach that seeks to identify vulnerabilities created when cancer cells lose or alter particular genes. Tango uses this strategy to find drug targets and develop investigational therapies for tumors with specific genetic alterations.